Research Article

Toxoplasma gondii Myocarditis after Adult Heart Transplantation: Successful Prophylaxis with Pyrimethamine

Tania Mara V. Strabelli,1 Rinaldo Focaccia Siciliano,1 Silvia Vidal Campos,2 Jussara Bianchi Castelli,3 Fernando Bacal,4 Edimar A. Bocchi,4 and David E. Uip1

1 Infection Control Unit, Heart Institute (Incor-HCFMUSP), University of São Paulo Medical School, São Paulo, SP, Brazil
2 Lung Transplant Unit, Heart Institute (Incor-HCFMUSP), University of São Paulo Medical School, São Paulo, SP, Brazil
3 Pathology Unit, Heart Institute (Incor-HCFMUSP), University of São Paulo Medical School, São Paulo, SP, Brazil
4 Heart Transplant Unit, Heart Institute (Incor-HCFMUSP), University of São Paulo Medical School, São Paulo, SP, Brazil

Correspondence should be addressed to Tania Mara V. Strabelli, tania.strabelli@incor.usp.br

Received 29 May 2012; Revised 24 September 2012; Accepted 2 October 2012

Academic Editor: Maria Aparecida Shikanai Yasuda

Copyright © 2012 Tania Mara V. Strabelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Toxoplasma gondii primary infection/reactivation after solid organ transplantation is a serious complication, due to the high mortality rate following disseminated disease. We performed a retrospective study of all cases of T. gondii infections in 436 adult patients who had received an orthotopic cardiac transplant at our Institution from May 1968 to January 2011. Six patients (1.3%) developed T. gondii infection/reactivation in the post-operative period. All infections/reactivations occurred before 1996, when no standardized toxoplasmosis prophylactic regimen or co-trimoxazole prophylaxis was used. Starting with the 112th heart transplant, oral pyrimethamine 75 mg/day was used for seronegative transplant recipients whose donors were seropositive or unknown. Two patients (33.3%) presented with disseminated toxoplasmosis infection, and all patients (100%) had myocarditis. Five patients (83.3%) were seronegative before transplant and one patient did not have pre-transplant serology available. Median time for infection onset was 131 days following transplantation. Three patients (50%) died due to toxoplasmosis infection. After 1996, we did not observe any additional cases of T. gondii infection/reactivation. In conclusion, toxoplasmosis in heart allografts was more frequent among seronegative heart recipients, and oral pyrimethamine was highly effective for the prevention of T. gondii infection in this population.

1. Background

Toxoplasmosis is a zoonotic disease of worldwide distribution, with a high incidence in certain countries. Humans are usually infected through ingestion of oocysts that are present in contaminated water or soil, or by eating undercooked meat with tissue cysts. Although the typical course of acute infection is a benign febrile syndrome in healthy patients, severe disease occurs in hosts with immune system impairment, including transplant and AIDS patients. Transplant recipients who are seronegative for Toxoplasma gondii are at particular risk of developing a severe toxoplasmosis infection upon receipt of an organ from a seropositive donor [1].

In this study, we studied six cases of T. gondii myocarditis following heart transplantation before routine use of pyrimethamine prophylaxis in our institution.

2. Patients and Methods

We performed a retrospective study of all cases of T. gondii infections in adult patients who had received an orthotopic cardiac transplant at our institution from May 1968 to January 2011. The Heart Institute (Incor-HCFMUSP) is a tertiary cardiology care hospital in São Paulo, Brazil, with a heart transplant program that was founded in 1964. Until 1996, there was no standardized toxoplasmosis prophylactic regimen. Starting with the 112th heart transplant, oral pyrimethamine 75 mg/day was used for seronegative transplant recipients whose donors were seropositive or unknown. This regimen was given from the first day after transplant and was maintained until the 100th day after transplant. Pneumocystis jiroveci pneumonia prophylaxis with cotrimoxazole was not used following heart transplant.
In this region of the myocardium, a small *Toxoplasma* pseudocyst was noted in one cardiomyocyte (arrow). The inset shows amplification of this area, as indicated by the arrow. The presence of round corpuscles consistent with *T. gondii* tachyzoites near the cardiomyocyte nucleus was noted. (b) In another region of the myocardium within the same endomyocardial biopsy sample, there were moderate amounts of mononuclear infiltrates with aggression and destruction of the cardiomyocyte. This led to the misdiagnosis of rejection, even though it was subsequently determined that this case of myocarditis was caused by *T. gondii*. ((a) and (b) Hematoxylin and eosin stain with objective ×40 in all images and digital zoom at the inset).

We diagnosed toxoplasmosis by analyzing the histology of endomyocardial biopsies and/or necropsies, in which *Toxoplasma* infection was determined by morphology using hematoxylin and eosin, and immunohistochemistry using commercially available polyclonal rabbit antibody against *T. gondii* (produced by Chemicon International, Inc., Temecula, CA, USA). Patient medical charts from all histologically confirmed *T. gondii* infections were reviewed.

### 3. Results

During the study period, 436 adult heart transplants were performed, and six patients (1.3%) developed *T. gondii* infection/reactivation in the postoperative period. All infections/reactivations occurred before 1996, and none of the patients received pyrimethamine prophylaxis. Demographic and clinical information are described in Table 1, and examples of histological examination are in Figures 1 and 2. All patients were seronegative for Chagas’ disease. Two patients (33.3%) presented with disseminated toxoplasmosis infection, and all patients (100%) had myocarditis. Five patients (83.3%) were *Toxoplasma* seronegative before transplant and one patient did not have before transplant serology available. Median time for *Toxoplasma* infection onset was 131 days (mean = 69 days, range 21–534) following transplantation. No seroconversion was detected. Three patients (50%) died due to toxoplasmosis infection. After 1996, we did not observe any additional cases of *T. gondii* infection/reactivation.

### 4. Discussion

*T. gondii* primary infection/reactivation after solid organ transplantation is a serious complication, due to the high mortality rate after disseminated disease. Following transplant, the parasitic infection is clearly related to the type and duration of suppressive therapy [1]. In a multicenter,
matched-case control study [2], the frequency of toxoplasmosis was significantly higher in heart recipients compared to the kidney and liver recipients. A negative serostatus prior to transplantation was the only independent risk factor for toxoplasmosis (odds ratio = 15.12 [95% confidence interval, 2.37–96.31]; P = .004). The central nervous system is mostly affected by this infection in AIDS patients [3]. Patients receiving heart transplants have a higher risk of developing T. gondii-induced myocarditis when compared with other solid organ transplants. Campbell et al. reviewed tissue-invasive toxoplasmosis in noncardiac solid organ transplant recipients (kidney, liver, small bowel, and pancreas) and found that in 52 cases, 44 (85%) patients had disseminated disease, while only 19% developed myocarditis [4]. Patients with toxoplasmosis after heart transplantation have myocarditis that may cause allograft dysfunction in 75%; disseminated disease occurs in nearly 45% of them [5]. Mortality due to Toxoplasma infection is also high. In a kidney transplant patient cohort with 31 cases of toxoplasmosis, 20 patients (64.5%) died [6]. In our study, we observed 50% mortality among the six infected patients. Death in most reported cases has been related to a delay in diagnosis and targeted treatment [2].

Endomyocardial biopsy (EMB) is a reliable way to identify and track rejection following heart transplantation, and in some cases, EMB may show the presence of infectious organisms, including Toxoplasma pseudocysts. Moreover, Toxoplasma is one of the most commonly opportunistic organisms diagnosed on EMB [7]. Toxoplasma-related myocarditis has a fugalusive exudative or neutrophilic component occurring when the myocyte ruptures following Toxoplasma proliferation. This fugalusive component becomes mononuclear shortly after rupture, which results in an increasingly difficult differential diagnosis of rejection.

Therefore, in some cases, the lymphoid infiltrate may not be caused by transplant rejection. In addition, the pseudocysts are often present in non-inflamed myocardial tissue, that is, when there is no myocyte rupture and the microorganism remains hidden from the immune system and may go unnoticed, even by a very experienced pathologist. This occurred in one case in our series of patients, where the review of a biopsy showed a small Toxoplasma pseudocyst present in a non-inflamed area of the myocardial sample. The use of T. gondii immunohistochemistry could help with the differential diagnosis of seronegative patients with suspected acute rejections (Figures 1 and 2). Consequently, we would like to caution the pathologist to be careful in their interpretation of tissue samples, considering the difficulty in visualizing Toxoplasma pseudocysts, as well as the difficulty in differentiating the diagnosis of rejection when inflammation is induced. In our series, five of six Toxoplasma infection presented as cardiac failure without fever. In the first months following cardiac transplant, this clinical situation could be misdiagnosed as cardiac failure without afever. In a review of two transplant programs in

### Table 1: Clinical and laboratorial data for six cases of *Toxoplasma* infection after cardiac transplantation without toxoplasmosis prophylaxis occurring before 1996.

| Patient sex/age (years) | Toxoplasmosis serostatus D/R—IgG | Time from transplant to toxoplasmosis diagnosis (days) | Source of diagnosis | Signs/symptoms | Treatment (days) | In-hospital lethal outcome* |
|------------------------|----------------------------------|------------------------------------------------------|--------------------|----------------|-----------------|----------------------------|
| M/52                   | NA/Neg                           | 21                                                   | EMB                | Heart failure  | S + P           | Yes                        |
| F/61                   | NA/Neg                           | 534                                                  | EMB                | None           | S + P           | No                         |
| M/44                   | NA/Neg                           | 70                                                   | EMB                | Heart failure  | S + P           | No                         |
| M/66                   | NA/NA                            | 69                                                   | Necropsy (CNS and heart)** | Heart failure and low-level consciousness | — | Yes                        |
| M/49                   | NA/Neg                           | 25                                                   | EMB                | Heart failure  | S + P           | No                         |
| F/49                   | NA/Neg                           | 69                                                   | Necropsy (CNS, heart and lungs) | Heart and respiratory failure and low-level consciousness | — | Yes                        |

Note: M: male; F: female; D/R: donor/recipient; NA: not available; Neg: negative; EMB: endomyocardial biopsy; CNS: central nervous system; S + P: sulfadiazine plus pyrimethamine.

*Survival after discharge not analyzed.

**The EMB was misdiagnosed as a rejection, and the patient subsequently received methylprednisolone 1 g/d for 3 days. At necropsy, the EMB was reviewed and the diagnosis of toxoplasmosis was determined.
the USA, Baran et al. found no evidence of toxoplasmosis postheart transplantation and proposed that *P. jiroveci* prophylaxis with cotrimoxazole is sufficient to prevent toxoplasmosis infection/reactivation [13]. Our heart transplant program does not recommend routine prophylaxis with cotrimoxazole for pneumocystosis prevention. In areas with a high prevalence of toxoplasmosis (50%–80% in adults), such as in Brazil [14], there is a low number of seronegative patients receiving heart transplants, and the prophylaxis could be individualized. Considering the adverse events related to universal *P. jiroveci* prophylaxis with cotrimoxazole (i.e., skin rashes or nephrotoxicity) and the low risk of pneumocystosis, we adopted the use of pyrimethamine as *Toxoplasma* prophylaxis in seronegative recipients. The reactivation of *T. gondii* within seropositive recipients is rare following heart transplantation [15]. We did not observe any incidents of *T. gondii* reactivation (IgG-positive recipients) in 43 years of cardiac transplant experience.

In conclusion, toxoplasmosis in heart allografts was more frequent among seronegative heart recipients, and oral pyrimethamine was highly effective for the prevention of *T. gondii* infection in this population.

**References**

[1] F. Derouin, H. Pelloux, and ESCMID Study Group on Clinical Parasitology, “Prevention of toxoplasmosis in transplant patients,” *Clinical Microbiology and Infection*, vol. 14, no. 12, pp. 1089–1101, 2008.

[2] N. Fernandez-Sabé, C. Cervera, M. C. Fariñas et al., “Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study,” *Clinical Infectious Diseases*, vol. 54, no. 3, pp. 355–361, 2012.

[3] V. L. Pereira-Chioccola, J. E. Vidal, and C. Su, “Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients,” *Future Microbiology*, vol. 4, no. 10, pp. 1363–1379, 2009.

[4] A. L. Campbell, C. L. Goldberg, M. S. Magid, G. Gondolesi, C. Rumbo, and B. C. Herold, “First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following non-cardiac solid organ transplantation,” *Transplantation*, vol. 81, no. 3, pp. 408–417, 2006.

[5] M. G. Michaels, E. R. Wald, F. J. Fricker, P. J. del Nido, and J. Armitage, “Toxoplasmosis in pediatric recipients of heart transplants,” *Clinical Infectious Diseases*, vol. 14, no. 4, pp. 847–851, 1992.

[6] E. Renoult, E. Georges, M. F. Biava et al., “Toxoplasmosis in kidney transplant recipients: report of six cases and review,” *Clinical Infectious Diseases*, vol. 24, no. 4, pp. 625–634, 1997.

[7] L. G. Winters and F. J. Schoen, “Pathology of cardiac transplantation,” in *Cardiovascular Pathology*, M. D. Silver, A. I. Gotlieb, and F. J. Schoen, Eds., p. 742, WB Saunders, Philadelphia, Pa, USA, 3rd edition, 2001.

[8] T. G. Wreghitt, M. Hakim, J. J. Gray et al., “Toxoplasmosis in heart and heart and lung transplant recipients,” *Journal of Clinical Pathology*, vol. 42, no. 2, pp. 194–199, 1989.

[9] M. Hakim, D. Esmore, J. Wallwork, T. A. English, and T. Wreghitt, “Toxoplasmosis in cardiac transplantation,” *British Medical Journal*, vol. 292, no. 6528, p. 1108, 1986.

[10] P. Muñoz, J. Arencibia, C. Rodriguez et al., “Trimethoprim-sulfamethoxazole as toxoplasmosis prophylaxis for heart transplant recipients,” *Clinical Infectious Diseases*, vol. 36, no. 7, pp. 932–933, 2003.

[11] L. R. Baden, J. T. Katz, L. Franck et al., “Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole,” *Transplantation*, vol. 75, no. 3, pp. 339–343, 2003.

[12] S. Gourishankar, K. Doucette, J. Fenton, D. Purrych, K. Kowalewska-Grochowska, and J. Preiksaitis, “The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis,” *Transplantation*, vol. 85, no. 7, pp. 980–985, 2008.

[13] D. A. Baran, M. M. Alwarshetty, S. Alvi et al., “Is toxoplasmosis prophylaxis necessary in cardiac transplantation? Long-term follow-up at two transplant centers,” *Journal of Heart and Lung Transplantation*, vol. 25, no. 11, pp. 1380–1382, 2006.

[14] J. K. Frenkel and J. E. V. Bermudez, “Toxoplasmosis,” in *Veronesi: Tratado de Infectologia*, chapter 99, pp. 1633–1650, Editora Atheneu, São Paulo, Brazil, 3rd edition, 2005.

[15] M. Castagnini, S. Bernazzali, C. Ginanneschi et al., “Fatal disseminated toxoplasmosis in a cardiac transplantation with seropositive match for toxoplasma: should prophylaxis be extended?” *Transplant Immunology*, vol. 18, no. 2, pp. 193–197, 2007.